BTG raises full-year guidance on acquisition, settlements and milestone
This article was originally published in Scrip
On the day it expects to close its £177 million acquisition of drug delivery specialist Biocompatibles, BTG raised its guidance for full-year revenues to £108-£114 million, from £93-£97 million previously, to take account of Biocompatibles' contribution, revenues from legal settlements and a milestone related to the prostate cancer therapy abiraterone acetate.
You may also be interested in...
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.
Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.